| Device |
respiratory specimen nucleic acid sars-cov-2 test |
| Definition |
A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors. |
| Physical State |
A test system that contains all necessary reagents for sample preparation, nucleic acid reverse transcription and amplification, and detection from SARS-CoV-2 nucleic acids from a single respiratory tract specimen. |
| Technical Method |
A nucleic acid amplification test (NAAT). |
| Target Area |
Human respiratory tract specimens, such as anterior nasal swabs, nasopharyngeal swabs, nasal or nasopharyngeal washes and aspirates, etc. |
| Regulation Medical Specialty |
Microbiology |
| Review Panel |
Microbiology |
|---|
| Product Code | QQX |
|---|
| Premarket Review |
Office of In Vitro Diagnostics
(OHT7)
Division of Microbiology Devices
(DMD)
|
| Submission Type |
510(k)
|
|---|
| Regulation Number |
866.3981
|
|---|
| Device Class |
2
|
| Total Product Life Cycle (TPLC) |
TPLC Product Code Report
|
| GMP Exempt? |
No
|
Summary Malfunction
Reporting |
Ineligible |
| Implanted Device? |
No
|
|---|
| Life-Sustain/Support Device? |
No
|
|---|
| Third Party Review |
Not Third Party Eligible |
